Modulation of host lung immunity in Pneumocystis pneumonia: a review of current concepts and future prospects for novel adjunctive immune-based therapies
The Journal of Immunology · 2025
DOI: 10.1093/jimmun/vkaf269 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Immunology, 2025. Verfasst von Theodore J Kottom und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic Diseases Research, Department of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine, Rochester, MN, United St…. Hauptthemen laut MEDLINE: Pneumonia, Pneumocystis, Lung, Pneumocystis carinii, Immunotherapy. Die Arbeit nennt 132 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIAID NIH HHS, NIH HHS.
Abstract (Originalsprache)
Pneumocystis jirovecii pneumonia remains a significant cause of mortality and morbidity in immunocompromised populations worldwide. Mortality rates range from 5% to 30% in HIV-positive individuals and 4% to 76% in those without HIV. Recognizing its public health impact, the World Health Organization (WHO) included Pneumocystis jirovecii in its 2022 “Fungal Priority Pathogens” list. In this review, we will summarize published findings over the last 14 years on the immunopathogenic mechanisms underlying Pneumocystis pneumonia–related lung injury and examine the potential for targeting these pathways in adjunctive immune modulation therapy. Notably, recent studies have identified promising immune-based interventions, including PD-1/PD-L1 blockade and IL-7 therapy, which may enhance pathogen clearance while controlling damaging inflammation. Additionally, small molecule inhibitors such as BRD5529 and ALW-II-41-27 have shown potential in reducing lung injury by modulating proinflammatory signaling pathways in Pneumocystis pneumonia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Thoracic Diseases Research, Department of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine, Rochester, MN, United States.
ORCID-Profile: Theodore J Kottom
Förderung
- NHLBI NIH HHS
- NIAID NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Kottom, T. J., & Limper, A. H. (2025). Modulation of host lung immunity in Pneumocystis pneumonia: a review of current concepts and future prospects for novel adjunctive immune-based therapies. The Journal of Immunology. https://doi.org/10.1093/jimmun/vkaf269
Vancouver
Kottom TJ, Limper AH. Modulation of host lung immunity in Pneumocystis pneumonia: a review of current concepts and future prospects for novel adjunctive immune-based therapies. The Journal of Immunology. 2025. doi:10.1093/jimmun/vkaf269
BibTeX
@article{Kottom2025,
author = {Kottom, Theodore J and Limper, Andrew H},
title = {Modulation of host lung immunity in Pneumocystis pneumonia: a review of current concepts and future prospects for novel adjunctive immune-based therapies},
journal = {The Journal of Immunology},
year = {2025},
doi = {10.1093/jimmun/vkaf269}
}
EUVIMED